However, results from the ClarIDHy phase III clinical trial 17 revealed that though ivosidenib-treated ICC patients showed prolonged median overall survival compared to placebo controls, this improvement did not reach statistical significance.
← all excerpts
MYC-Mediated Functional Manifestation of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Confers Sensitivity to (+)-JQ1.
1
—
—